Your Input:
|
||||
PDXP | pyridoxal (pyridoxine, vitamin B6) phosphatase; Protein serine phosphatase that dephosphorylates ’Ser-3’ in cofilin and probably also dephosphorylates phospho-serine residues in DSTN. Regulates cofilin-dependent actin cytoskeleton reorganization. Required for normal progress through mitosis and normal cytokinesis. Does not dephosphorylate phospho-threonines in LIMK1. Does not dephosphorylate peptides containing phospho- tyrosine. Pyridoxal phosphate phosphatase. Has some activity towards pyridoxal 5’-phosphate (PLP), pyridoxine 5’-phosphate (PMP) and pyridoxine 5’-phosphate (PNP), with [...] (296 aa) | |||
CTSG | cathepsin G; Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe- CH2Cl and phenylmethylsulfonyl fluoride (255 aa) | |||
F9 | coagulation factor IX; Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa (461 aa) | |||
GZMM | granzyme M (lymphocyte met-ase 1); Cleaves peptide substrates after methionine, leucine, and norleucine. Physiological substrates include EZR, alpha- tubulins and the apoptosis inhibitor BIRC5/Survivin. Promotes caspase activation and subsequent apoptosis of target cells (257 aa) | |||
GZMA | granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3); This enzyme is necessary for target cell lysis in cell- mediated immune responses. It cleaves after Lys or Arg. Cleaves APEX1 after ’Lys-31’ and destroys its oxidative repair activity. Involved in apoptosis (262 aa) | |||
TMPRSS11D | transmembrane protease, serine 11D; May play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions (418 aa) | |||
C1R | complement component 1, r subcomponent (668 aa) | |||
CTRB2 | chymotrypsinogen B2 (263 aa) | |||
PRSS8 | protease, serine, 8; Possesses a trypsin-like cleavage specificity with a preference for poly-basic substrates. Stimulates epithelial sodium channel (ENaC) activity through activating cleavage of the gamma subunits (SCNN1G) (343 aa) | |||
TMPRSS11B | transmembrane protease, serine 11B; Probable serine protease (By similarity) (416 aa) | |||
PGP | phosphoglycolate phosphatase (321 aa) | |||
RIPK4 | receptor-interacting serine-threonine kinase 4; Involved in stratified epithelial development. It is a direct transcriptional target of TP63. Plays a role in NF-kappa-B activation (784 aa) | |||
KLK5 | kallikrein-related peptidase 5; May be involved in desquamation (293 aa) | |||
TPSAB1 | tryptase alpha/beta 1; Tryptase is the major neutral protease present in mast cells and is secreted upon the coupled activation-degranulation response of this cell type. Has an immunoprotective role during bacterial infection. Required to efficiently combat K.pneumoniae infection (By similarity) (275 aa) | |||
TMPRSS11F | transmembrane protease, serine 11F; Probable serine protease (By similarity) (438 aa) | |||
ANGPTL2 | angiopoietin-like 2; Induces sprouting in endothelial cells through an autocrine and paracrine action (493 aa) | |||
F7 | coagulation factor VII (serum prothrombin conversion accelerator); Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium (466 aa) | |||
LILRB2 | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2; Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance. Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (598 aa) | |||
KLK7 | kallikrein-related peptidase 7; May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. SCCE cleaves insulin B chain at ’6-Leu-|-Cys-7’, ’16-Tyr-|-Leu-17’, ’25-Phe-|-Tyr-26’ and ’26-Tyr-|-Thr-27’. Could play a role in the activation of precursors to inflammatory cytokines (253 aa) | |||
ACAN | aggrecan; This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region (2530 aa) | |||
PRSS42 | protease, serine, 42 (293 aa) | |||
ENSG00000244255 | Complement factor B Ba fragment; Uncharacterized protein; cDNA FLJ55673, highly similar to Complement factor B (1266 aa) | |||
PRSS46 | protease, serine, 46 (174 aa) | |||
MST1L | macrophage stimulating 1-like (715 aa) | |||
KLK15 | kallikrein-related peptidase 15; Protease whose physiological substrate is not yet known (256 aa) | |||
KLK13 | kallikrein-related peptidase 13 (277 aa) |